MIF and CXCL12 in cardiovascular diseases: Functional differences and similarities

Frontiers in Immunology

Volumn 6, Issue JUL, 2015, Pages

  van der Vorst, Emiel P C ^a   Döring, Yvonne ^a   Weber, Christian ^a,b,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Cardiovascular disease; Chemokines; CXCL12; Macrophage migration inhibitory factor

Indexed keywords

CD74 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HERMES ANTIGEN; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRIX METALLOPROTEINASE; PLERIXAFOR; TOLL LIKE RECEPTOR 4; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN;

APOPTOSIS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOWN REGULATION; HEMATOPOIESIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; PHYSICAL INACTIVITY; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SOCIAL PSYCHOLOGY; STEM CELL MOBILIZATION;

EID: 84938493398     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00373     Document Type: Review

References (170)

1. Dahlof B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol (2010) 105(1 Suppl):3A-9A. doi:10.1016/j.amjcard.2009.10.007
2. Lloyd-Jones DM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation (2010) 121(15):1768-77. doi:10.1161/CIRCULATIONAHA.109.849166
3. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2013 update: a report from the American heart association. Circulation (2013) 127(1):e6-245. doi:10.1161/CIR.0b013e318282ab8f
4. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 352(16):1685-95. doi:10.1056/NEJMra043430
5. Farouk SS, Rader DJ, Reilly MP, Mehta NN. CXCL12: a new player in coronary disease identified through human genetics. Trends Cardiovasc Med (2010) 20(6):204-9. doi:10.1016/j.tcm.2011.08.002
6. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res (2000) 86(2):131-8. doi:10.1161/01.RES.86.2.131
7. Stellos K, Bigalke B, Langer H, Geisler T, Schad A, Kogel A, et al. Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells. Eur Heart J (2009) 30(5):584-93. doi:10.1093/eurheartj/ehn566
8. Rath D, Chatterjee M, Borst O, Muller K, Stellos K, Mack AF, et al. Expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary syndrome and association with left ventricular functional recovery. Eur Heart J (2014) 35(6):386-94. doi:10.1093/eurheartj/eht448
9. Damas JK, Waehre T, Yndestad A, Ueland T, Muller F, Eiken HG, et al. Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation (2002) 106(1):36-42. doi:10.1161/01.CIR.0000020001.09990.90
10. Ghasemzadeh N, Hritani AW, De Staercke C, Eapen DJ, Veledar E, Al Kassem H, et al. Plasma stromal cell-derived factor 1alpha/CXCL12 level predicts long-term adverse cardiovascular outcomes in patients with coronary artery disease. Atherosclerosis (2015) 238(1):113-8. doi:10.1016/j.atherosclerosis.2014.10.094
11. Wurster T, Stellos K, Haap M, Seizer P, Geisler T, Otton J, et al. Platelet expression of stromal-cell-derived factor-1 (SDF-1): an indicator for ACS?. Int J Cardiol (2013) 164(1):111-5. doi:10.1016/j.ijcard.2011.06.082
12. Tereshchenko IP, Petrkova J, Mrazek F, Lukl J, Maksimov VN, Romaschenko AG, et al. The macrophage migration inhibitory factor (MIF) gene polymorphism in Czech and Russian patients with myocardial infarction. Clin Chim Acta (2009) 402(1-2):199-202. doi:10.1016/j.cca.2008.12.034
13. Burger-Kentischer A, Goebel H, Seiler R, Fraedrich G, Schaefer HE, Dimmeler S, et al. Expression of macrophage migration inhibitory factor in different stages of human atherosclerosis. Circulation (2002) 105(13):1561-6. doi:10.1161/01.CIR.0000012942.49244.82
14. Kong YZ, Huang XR, Ouyang X, Tan JJ, Fingerle-Rowson G, Bacher M, et al. Evidence for vascular macrophage migration inhibitory factor in destabilization of human atherosclerotic plaques. Cardiovasc Res (2005) 65(1):272-82. doi:10.1016/j.cardiores.2004.09.020
15. Müller II, Müller KA, Schönleber H, Karathanos A, Schneider M, Jorbenadze R, et al. Macrophage migration inhibitory factor is enhanced in acute coronary syndromes and is associated with the inflammatory response. PLoS One (2012) 7(6):e38376. doi:10.1371/journal.pone.0038376
16. Makino A, Nakamura T, Hirano M, Kitta Y, Sano K, Kobayashi T, et al. High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis (2010) 213(2):573-8. doi:10.1016/j.atherosclerosis.2010.09.004
17. Müller II, Müller KA, Karathanos A, Schönleber H, Rath D, Vogel S, et al. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor gremlin-1 in patients with coronary artery disease. Atherosclerosis (2014) 237(2):426-32. doi:10.1016/j.atherosclerosis.2014.09.010
18. Chan W, White DA, Wang XY, Bai RF, Liu Y, Yu HY, et al. Macrophage migration inhibitory factor for the early prediction of infarct size. J Am Heart Assoc (2013) 2(5):e000226. doi:10.1161/JAHA.113.000226
19. Boekholdt SM, Peters RJ, Day NE, Luben R, Bingham SA, Wareham NJ, et al. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk prospective population study. Am J Med (2004) 117(6):390-7. doi:10.1016/j.amjmed.2004.04.010
20. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet (2004) 364(9438):953-62. doi:10.1016/S0140-6736(04)17019-0
21. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 364(9438):937-52. doi:10.1016/S0140-6736(04)17018-9
22. Nahrendorf M, Swirski FK. Lifestyle effects on hematopoiesis and atherosclerosis. Circ Res (2015) 116(5):884-94. doi:10.1161/CIRCRESAHA.116.303550
23. Kovacic S, Bakran M. Genetic susceptibility to atherosclerosis. Stroke Res Treat (2012) 2012:362941. doi:10.1155/2012/362941
24. Zarins CK, Giddens DP, Bharadvaj BK, Sottiurai VS, Mabon RF, Glagov S. Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res (1983) 53(4):502-14. doi:10.1161/01.RES.53.4.502
25. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol (1995) 15(5):551-61. doi:10.1161/01.ATV.15.5.551
26. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol (2011) 12(3):204-12. doi:10.1038/ni.2001
27. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell (2001) 104(4):503-16. doi:10.1016/S0092-8674(01)00238-0
28. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem (2002) 277(51):49982-8. doi:10.1074/jbc.M209649200
29. Pluddemann A, Neyen C, Gordon S. Macrophage scavenger receptors and host-derived ligands. Methods (2007) 43(3):207-17. doi:10.1016/j.ymeth.2007.06.004
30. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature (2005) 438(7068):612-21. doi:10.1038/nature04399
31. Brown MS, Ho YK, Goldstein JL. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem (1980) 255(19):9344-52.
32. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab (2008) 7(5):365-75. doi:10.1016/j.cmet.2008.03.001
33. Wang J, Tong C, Yan X, Yeung E, Gandavadi S, Hare AA, et al. Limiting cardiac ischemic injury by pharmacological augmentation of macrophage migration inhibitory factor-AMP-activated protein kinase signal transduction. Circulation (2013) 128(3):225-36. doi:10.1161/CIRCULATIONAHA.112.000862
34. Murphy AJ, Dragoljevic D, Tall AR. Cholesterol efflux pathways regulate myelopoiesis: a potential link to altered macrophage function in atherosclerosis. Front Immunol (2014) 5:490. doi:10.3389/fimmu.2014.00490
35. McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res (2011) 50(4):331-47. doi:10.1016/j.plipres.2011.04.002
36. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood (1989) 74(7):2527-34.
37. Gautier EL, Jakubzick C, Randolph GJ. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 29(10):1412-8. doi:10.1161/ATVBAHA.108.180505
38. Wong KL, Tai JJ, Wong WC, Han H, Sem X, Yeap WH, et al. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood (2011) 118(5):e16-31. doi:10.1182/blood-2010-12-326355
39. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity (2000) 12(2):121-7. doi:10.1016/S1074-7613(00)80165-X
40. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity (2003) 19(1):71-82. doi:10.1016/S1074-7613(03)00174-2
41. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol (2010) 7(2):77-86. doi:10.1038/nrcardio.2009.228
42. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, et al. Nomenclature of monocytes and dendritic cells in blood. Blood (2010) 116(16):e74-80. doi:10.1182/blood-2010-02-258558
43. Sunderkotter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol (2004) 172(7):4410-7. doi:10.4049/jimmunol.172.7.4410
44. Zernecke A, Bot I, Djalali-Talab Y, Shagdarsuren E, Bidzhekov K, Meiler S, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res (2008) 102(2):209-17. doi:10.1161/CIRCRESAHA.107.160697
45. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol (2008) 28(11):1897-908. doi:10.1161/ATVBAHA.107.161174
46. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 117(1):195-205. doi:10.1172/JCI29950
47. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol (2013) 13(10):709-21. doi:10.1038/nri3520
48. Barreiro O, Yanez-Mo M, Serrador JM, Montoya MC, Vicente-Manzanares M, Tejedor R, et al. Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol (2002) 157(7):1233-45. doi:10.1083/jcb.200112126
49. Gerhardt T, Ley K. Monocyte trafficking across the vessel wall. Cardiovasc Res (2015) pii:cvv147. doi:10.1093/cvr/cvv147
50. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med (2011) 17(11):1410-22. doi:10.1038/nm.2538
51. Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol (2007) 7(6):467-77. doi:10.1038/nri2096
52. Carman CV, Springer TA. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J Cell Biol (2004) 167(2):377-88. doi:10.1083/jcb.200404129
53. Johnson JL, Newby AC. Macrophage heterogeneity in atherosclerotic plaques. Curr Opin Lipidol (2009) 20(5):370-8. doi:10.1097/MOL.0b013e3283309848
54. Shimada K. Immune system and atherosclerotic disease: heterogeneity of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ J (2009) 73(6):994-1001. doi:10.1253/circj.CJ-09-0277
55. Wolfs IM, Donners MM, de Winther MP. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost (2011) 106(5):763-71. doi:10.1160/TH11-05-0320
56. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol (2010) 10(1):36-46. doi:10.1038/nri2675
57. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol (2011) 13(3):184-90. doi:10.1038/ncb0311-184
58. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol (2002) 15(6):439-46. doi:10.1111/j.1540-8183.2002.tb01087.x
59. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell (2011) 145(3):341-55. doi:10.1016/j.cell.2011.04.005
60. Lusis AJ. Atherosclerosis. Nature (2000) 407(6801):233-41. doi:10.1038/35025203
61. Blanchet X, Langer M, Weber C, Koenen RR, von Hundelshausen P. Touch of chemokines. Front Immunol (2012) 3:175. doi:10.3389/fimmu.2012.00175
62. Rajagopalan L, Rajarathnam K. Structural basis of chemokine receptor function-a model for binding affinity and ligand selectivity. Biosci Rep (2006) 26(5):325-39. doi:10.1007/s10540-006-9025-9
63. Asare Y, Schmitt M, Bernhagen J. The vascular biology of macrophage migration inhibitory factor (MIF). Expression and effects in inflammation, atherogenesis and angiogenesis. Thromb Haemost (2013) 109(3):391-8. doi:10.1160/TH12-11-0831
64. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, et al. International union of basic and clinical pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2014) 66(1):1-79. doi:10.1124/pr.113.007724
65. Zernecke A, Weber C. Chemokines in atherosclerosis: proceedings resumed. Arterioscler Thromb Vasc Biol (2014) 34(4):742-50. doi:10.1161/ATVBAHA.113.301655
66. Zhou Z, Subramanian P, Sevilmis G, Globke B, Soehnlein O, Karshovska E, et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab (2011) 13(5):592-600. doi:10.1016/j.cmet.2011.02.016
67. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation (2010) 122(18):1837-45. doi:10.1161/CIRCULATIONAHA.110.961714
68. Soehnlein O, Drechsler M, Doring Y, Lievens D, Hartwig H, Kemmerich K, et al. Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol Med (2013) 5(3):471-81. doi:10.1002/emmm.201201717
69. Sheikine Y, Hansson GK. Chemokines and atherosclerosis. Ann Med (2004) 36(2):98-118. doi:10.1080/07853890310019961
70. Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest (2007) 117(1):185-94. doi:10.1172/JCI28549
71. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature (1998) 394(6696):894-7. doi:10.1038/29788
72. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol (2006) 7(3):311-7. doi:10.1038/ni1309
73. Landsman L, Bar-On L, Zernecke A, Kim KW, Krauthgamer R, Shagdarsuren E, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood (2009) 113(4):963-72. doi:10.1182/blood-2008-07-170787
74. Potteaux S, Combadiere C, Esposito B, Casanova S, Merval R, Ardouin P, et al. Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice. Mol Med (2005) 11(1-12):16-20. doi:10.2119/2005-00028.Potteaux
75. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E, et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2007) 27(2):373-9. doi:10.1161/01.ATV.0000253886.44609.ae
76. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A (2006) 103(10):3781-6. doi:10.1073/pnas.0511043103
77. Feig JE, Rong JX, Shamir R, Sanson M, Vengrenyuk Y, Liu J, et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A (2011) 108(17):7166-71. doi:10.1073/pnas.1016086108
78. Feig JE, Shang Y, Rotllan N, Vengrenyuk Y, Wu C, Shamir R, et al. Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One (2011) 6(12):e28534. doi:10.1371/journal.pone.0028534
79. Luchtefeld M, Grothusen C, Gagalick A, Jagavelu K, Schuett H, Tietge UJ, et al. Chemokine receptor 7 knockout attenuates atherosclerotic plaque development. Circulation (2010) 122(16):1621-8. doi:10.1161/CIRCULATIONAHA.110.956730
80. Segers D, Lipton JA, Leenen PJ, Cheng C, Tempel D, Pasterkamp G, et al. Atherosclerotic plaque stability is affected by the chemokine CXCL10 in both mice and humans. Int J Inflam (2011) 2011:936109. doi:10.4061/2011/936109
81. Murdoch C, Monk PN, Finn A. Cxc chemokine receptor expression on human endothelial cells. Cytokine (1999) 11(9):704-12. doi:10.1006/cyto.1998.0465
82. Fujiwara K, Matsukawa A, Ohkawara S, Takagi K, Yoshinaga M. Functional distinction between CXC chemokines, interleukin-8 (IL-8), and growth related oncogene (GRO)alpha in neutrophil infiltration. Lab Invest (2002) 82(1):15-23. doi:10.1038/labinvest.3780391
83. Ali S, Lazennec G. Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev (2007) 26(3-4):401-20. doi:10.1007/s10555-007-9073-z
84. Yu L, Cecil J, Peng SB, Schrementi J, Kovacevic S, Paul D, et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene (2006) 374:174-9. doi:10.1016/j.gene.2006.02.001
85. Wang JF, Liu ZY, Groopman JE. The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood (1998) 92(3):756-64.
86. De La Luz Sierra M, Yang F, Narazaki M, Salvucci O, Davis D, Yarchoan R, et al. Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood (2004) 103(7):2452-9. doi:10.1182/blood-2003-08-2857
87. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res (2010) 16(11):2927-31. doi:10.1158/1078-0432.CCR-09-2329
88. Orsini MJ, Parent JL, Mundell SJ, Marchese A, Benovic JL. Trafficking of the HIV coreceptor CXCR4. Role of arrestins and identification of residues in the c-terminal tail that mediate receptor internalization. J Biol Chem (1999) 274(43):31076-86. doi:10.1074/jbc.274.43.31076
89. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem (2005) 280(42):35760-6. doi:10.1074/jbc.M508234200
90. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med (2006) 203(9):2201-13. doi:10.1084/jem.20052144
91. Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene (2010) 29(32):4599-610. doi:10.1038/onc.2010.212
92. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One (2010) 5(2):e9175. doi:10.1371/journal.pone.0009175
93. Sanchez-Alcaniz JA, Haege S, Mueller W, Pla R, Mackay F, Schulz S, et al. Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron (2011) 69(1):77-90. doi:10.1016/j.neuron.2010.12.006
94. Uto-Konomi A, McKibben B, Wirtz J, Sato Y, Takano A, Nanki T, et al. CXCR7 agonists inhibit the function of CXCL12 by down-regulation of CXCR4. Biochem Biophys Res Commun (2013) 431(4):772-6. doi:10.1016/j.bbrc.2013.01.032
95. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol (2009) 75(5):1240-7. doi:10.1124/mol.108.053389
96. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, et al. Beta-arrestin but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S A (2010) 107(2):628-32. doi:10.1073/pnas.0912852107
97. Döring Y, Pawig L, Weber C, Noels H. The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease. Front Physiol (2014) 5:212. doi:10.3389/fphys.2014.00212
98. Guo Y, Hangoc G, Bian H, Pelus LM, Broxmeyer HE. SDF-1/CXCL12 enhances survival and chemotaxis of murine embryonic stem cells and production of primitive and definitive hematopoietic progenitor cells. Stem Cells (2005) 23(9):1324-32. doi:10.1634/stemcells.2005-0085
99. Mazo IB, Massberg S, von Andrian UH. Hematopoietic stem and progenitor cell trafficking. Trends Immunol (2011) 32(10):493-503. doi:10.1016/j.it.2011.06.011
100. Dar A, Schajnovitz A, Lapid K, Kalinkovich A, Itkin T, Ludin A, et al. Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia (2011) 25(8):1286-96. doi:10.1038/leu.2011.62
101. Du F, Zhou J, Gong R, Huang X, Pansuria M, Virtue A, et al. Endothelial progenitor cells in atherosclerosis. Front Biosci (Landmark Ed) (2012) 17:2327-49. doi:10.2741/4055
102. Merkulova-Rainon T, Broqueres-You D, Kubis N, Silvestre JS, Levy BI. Towards the therapeutic use of vascular smooth muscle progenitor cells. Cardiovasc Res (2012) 95(2):205-14. doi:10.1093/cvr/cvs097
103. Akhtar S, Gremse F, Kiessling F, Weber C, Schober A. CXCL12 promotes the stabilization of atherosclerotic lesions mediated by smooth muscle progenitor cells in apoe-deficient mice. Arterioscler Thromb Vasc Biol (2013) 33(4):679-86. doi:10.1161/ATVBAHA.112.301162
104. Zoll J, Fontaine V, Gourdy P, Barateau V, Vilar J, Leroyer A, et al. Role of human smooth muscle cell progenitors in atherosclerotic plaque development and composition. Cardiovasc Res (2008) 77(3):471-80. doi:10.1093/cvr/cvm034
105. Yao L, Heuser-Baker J, Herlea-Pana O, Iida R, Wang Q, Zou MH, et al. Bone marrow endothelial progenitors augment atherosclerotic plaque regression in a mouse model of plasma lipid lowering. Stem Cells (2012) 30(12):2720-31. doi:10.1002/stem.1256
106. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem (1998) 273(7):4282-7. doi:10.1074/jbc.273.7.4282
107. Murphy PM, Baggiolini M I, Charo F, Hebert CA, Horuk R, Matsushima K, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000) 52(1):145-76.
108. Bruhl H, Cohen CD, Linder S, Kretzler M, Schlondorff D, Mack M. Post-translational and cell type-specific regulation of CXCR4 expression by cytokines. Eur J Immunol (2003) 33(11):3028-37. doi:10.1002/eji.200324163
109. Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR, Zou YR. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med (2004) 200(9):1145-56. doi:10.1084/jem.20041185
110. Nemenoff RA, Horita H, Ostriker AC, Furgeson SB, Simpson PA, Van Putten V, et al. SDF-1alpha induction in mature smooth muscle cells by inactivation of PTEN is a critical mediator of exacerbated injury-induced neointima formation. Arterioscler Thromb Vasc Biol (2011) 31(6):1300-8. doi:10.1161/ATVBAHA.111.223701
111. Gupta SK, Pillarisetti K, Lysko PG. Modulation of CXCR4 expression and SDF-1alpha functional activity during differentiation of human monocytes and macrophages. J Leukoc Biol (1999) 66(1):135-43.
112. Tanaka G, Nakase I, Fukuda Y, Masuda R, Oishi S, Shimura K, et al. CXCR4 stimulates macropinocytosis: implications for cellular uptake of arginine-rich cell-penetrating peptides and HIV. Chem Biol (2012) 19(11):1437-46. doi:10.1016/j.chembiol.2012.09.011
113. Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood (2009) 113(19):4711-9. doi:10.1182/blood-2008-09-177287
114. Martin C, Burdon PC, Bridger G, Gutierrez-Ramos JC, Williams TJ, Rankin SM. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity (2003) 19(4):583-93. doi:10.1016/S1074-7613(03)00263-2
115. Li LX, Zhang XF, Bai X, Tong Q. SDF-1 promotes ox-LDL induced vascular smooth muscle cell proliferation. Cell Biol Int (2013) 37(9):988-94. doi:10.1002/cbin.10126
116. Melchionna R, Porcelli D, Mangoni A, Carlini D, Liuzzo G, Spinetti G, et al. Laminar shear stress inhibits CXCR4 expression on endothelial cells: functional consequences for atherogenesis. FASEB J (2005) 19(6):629-31.
117. Saxena A, Fish JE, White MD, Yu S, Smyth JW, Shaw RM, et al. Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation (2008) 117(17):2224-31. doi:10.1161/CIRCULATIONAHA.107.694992
118. Poznansky MC I, Olszak T, Foxall R, Evans RH, Luster AD, Scadden DT. Active movement of T cells away from a chemokine. Nat Med (2000) 6(5):543-8. doi:10.1038/75022
119. Okabe S, Fukuda S, Kim YJ, Niki M, Pelus LM, Ohyashiki K, et al. Stromal cell-derived factor-1alpha/CXCL12-induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p62Dok-1. Blood (2005) 105(2):474-80. doi:10.1182/blood-2004-03-0843
120. Zhang X, Nakajima T, Goronzy JJ, Weyand CM. Tissue trafficking patterns of effector memory CD4+ T cells in rheumatoid arthritis. Arthritis Rheum (2005) 52(12):3839-49. doi:10.1002/art.21482
121. Klasen C, Ohl K, Sternkopf M, Shachar I, Schmitz C, Heussen N, et al. MIF promotes B cell chemotaxis through the receptors CXCR4 and CD74 and ZAP-70 signaling. J Immunol (2014) 192(11):5273-84. doi:10.4049/jimmunol.1302209
122. Kowalska MA, Ratajczak J, Hoxie J, Brass LF, Gewirtz A, Poncz M, et al. Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: determination of response to stromal-derived factor-1 by megakaryocytes and platelets. Br J Haematol (1999) 104(2):220-9. doi:10.1046/j.1365-2141.1999.01169.x
123. Chatterjee M, Gawaz M. Platelet-derived CXCL12 (SDF-1alpha): basic mechanisms and clinical implications. J Thromb Haemost (2013) 11(11):1954-67. doi:10.1111/jth.12404
124. Kraemer BF, Borst O, Gehring EM, Schoenberger T, Urban B, Ninci E, et al. PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1). J Mol Med (Berl) (2010) 88(12):1277-88. doi:10.1007/s00109-010-0680-8
125. Li X, Zhu M, Penfold ME, Koenen RR, Thiemann A, Heyll K, et al. Activation of CXCR7 limits atherosclerosis and improves hyperlipidemia by increasing cholesterol uptake in adipose tissue. Circulation (2014) 129(11):1244-53. doi:10.1161/CIRCULATIONAHA.113.006840
126. Lo Celso C, Fleming HE, Wu JW, Zhao CX, Miake-Lye S, Fujisaki J, et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature (2009) 457(7225):92-6. doi:10.1038/nature07434
127. Hu X, Dai S, Wu WJ, Tan W, Zhu X, Mu J, et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation (2007) 116(6):654-63. doi:10.1161/CIRCULATIONAHA.106.672451
128. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet (2003) 362(9385):697-703. doi:10.1016/S0140-6736(03)14232-8
129. Jujo K, Hamada H, Iwakura A, Thorne T, Sekiguchi H, Clarke T, et al. CXCR4 blockade augments bone marrow progenitor cell recruitment to the neovasculature and reduces mortality after myocardial infarction. Proc Natl Acad Sci U S A (2010) 107(24):11008-13. doi:10.1073/pnas.0914248107
130. Jujo K, Ii M, Sekiguchi H, Klyachko E, Misener S, Tanaka T, et al. CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism. Circulation (2013) 127(1):63-73. doi:10.1161/CIRCULATIONAHA.112.099242
131. Dai S, Yuan F, Mu J, Li C, Chen N, Guo S, et al. Chronic AMD3100 antagonism of SDF-1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction. J Mol Cell Cardiol (2010) 49(4):587-97. doi:10.1016/j.yjmcc.2010.07.010
132. Schober A, Knarren S, Lietz M, Lin EA, Weber C. Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation (2003) 108(20):2491-7. doi:10.1161/01.CIR.0000099508.76665.9A
133. Karshovska E, Zagorac D, Zernecke A, Weber C, Schober A. A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury. J Thromb Haemost (2008) 6(10):1812-5. doi:10.1111/j.1538-7836.2008.03086.x
134. Olive M, Mellad JA, Beltran LE, Ma M, Cimato T, Noguchi AC, et al. p21Cip1 modulates arterial wound repair through the stromal cell-derived factor-1/CXCR4 axis in mice. J Clin Invest (2008) 118(6):2050-61. doi:10.1172/JCI31244
135. Noels H, Zhou B, Tilstam PV, Theelen W, Li X, Pawig L, et al. Deficiency of endothelial CXCR4 reduces reendothelialization and enhances neointimal hyperplasia after vascular injury in atherosclerosis-prone mice. Arterioscler Thromb Vasc Biol (2014) 34(6):1209-20. doi:10.1161/ATVBAHA.113.302878
136. Massberg S, Konrad I, Schürzinger K, Lorenz M, Schneider S, Zohlnhoefer D, et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med (2006) 203(5):1221-33. doi:10.1084/jem.20051772
137. Subramanian S, Liu C, Aviv A, Ho JE, Courchesne P, Muntendam P, et al. Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. Arterioscler Thromb Vasc Biol (2014) 34(9):2100-5. doi:10.1161/ATVBAHA.114.303579
138. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol (2003) 3(10):791-800. doi:10.1038/nri1200
139. Tillmann S, Bernhagen J, Noels H. Arrest functions of the MIF ligand/receptor axes in atherogenesis. Front Immunol (2013) 4:115. doi:10.3389/fimmu.2013.00115
140. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A (1966) 56(1):72-7. doi:10.1073/pnas.56.1.72
141. Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med (1994) 179(6):1895-902. doi:10.1084/jem.179.6.1895
142. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A (1996) 93(15):7849-54. doi:10.1073/pnas.93.15.7849
143. Nishihira J, Koyama Y, Mizue Y. Identification of macrophage migration inhibitory factor (MIF) in human vascular endothelial cells and its induction by lipopolysaccharide. Cytokine (1998) 10(3):199-205. doi:10.1006/cyto.1997.0276
144. Wymann D, Bluggel M, Kalbacher H, Blesken T, Akdis CA, Meyer HE, et al. Human B cells secrete migration inhibition factor (MIF) and present a naturally processed MIF peptide on HLA-DRB1*0405 by a FXXL motif. Immunology (1999) 96(1):1-9. doi:10.1046/j.1365-2567.1999.00652.x
145. Chen L, Yang G, Zhang X, Wu J, Gu Q, Wei M, et al. Induction of MIF expression by oxidized LDL via activation of NF-kappaB in vascular smooth muscle cells. Atherosclerosis (2009) 207(2):428-33. doi:10.1016/j.atherosclerosis.2009.05.021
146. Simons D, Grieb G, Hristov M, Pallua N, Weber C, Bernhagen J, et al. Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J Cell Mol Med (2011) 15(3):668-78. doi:10.1111/j.1582-4934.2010.01041.x
147. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature (1995) 377(6544):68-71. doi:10.1038/377068a0
148. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum (1999) 42(8):1601-8. doi:10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B
149. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med (2000) 6(2):164-70. doi:10.1038/72262
150. Mawhinney L, Armstrong ME, O'Reilly C, Bucala R, Leng L, Fingerle-Rowson G, et al. Macrophage migration inhibitory factor (MIF) enzymatic activity and lung cancer. Mol Med (2014) 20:729-35. doi:10.2119/molmed.2014.00136
151. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF signal transduction initiated by binding to CD74. J Exp Med (2003) 197(11):1467-76. doi:10.1084/jem.20030286
152. Borghese F, Clanchy FI. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opin Ther Targets (2011) 15(3):237-51. doi:10.1517/14728222.2011.550879
153. Shi X, Leng L, Wang T, Wang W, Du X, Li J, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity (2006) 25(4):595-606. doi:10.1016/j.immuni.2006.08.020
154. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 13(5):587-96. doi:10.1038/nm1567
155. Schwartz V, Lue H, Kraemer S, Korbiel J, Krohn R, Ohl K, et al. A functional heteromeric MIF receptor formed by CD74 and CXCR4. FEBS Lett (2009) 583(17):2749-57. doi:10.1016/j.febslet.2009.07.058
156. Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M, et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal (2006) 18(5):688-703. doi:10.1016/j.cellsig.2005.06.013
157. Sun J, Hartvigsen K, Chou MY, Zhang Y, Sukhova GK, Zhang J, et al. Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation (2010) 122(8):808-20. doi:10.1161/CIRCULATIONAHA.109.891887
158. Chatterjee M, Borst O, Walker B, Fotinos A, Vogel S, Seizer P, et al. Macrophage migration inhibitory factor limits activation-induced apoptosis of platelets via CXCR7-dependent Akt signaling. Circ Res (2014) 115(11):939-49. doi:10.1161/CIRCRESAHA.115.305171
159. Lin SG, Yu XY, Chen YX, Huang XR, Metz C, Bucala R, et al. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res (2000) 87(12):1202-8. doi:10.1161/01.RES.87.12.1202
160. Burger-Kentischer A, Gobel H, Kleemann R, Zernecke A, Bucala R, Leng L, et al. Reduction of the aortic inflammatory response in spontaneous atherosclerosis by blockade of macrophage migration inhibitory factor (MIF). Atherosclerosis (2006) 184(1):28-38. doi:10.1016/j.atherosclerosis.2005.03.028
161. Schober A, Bernhagen J, Thiele M, Zeiffer U, Knarren S, Roller M, et al. Stabilization of atherosclerotic plaques by blockade of macrophage migration inhibitory factor after vascular injury in apolipoprotein E-deficient mice. Circulation (2004) 109(3):380-5. doi:10.1161/01.CIR.0000109201.72441.09
162. Cheng Q, McKeown SJ, Santos L, Santiago FS, Khachigian LM, Morand EF, et al. Macrophage migration inhibitory factor increases leukocyte-endothelial interactions in human endothelial cells via promotion of expression of adhesion molecules. J Immunol (2010) 185(2):1238-47. doi:10.4049/jimmunol.0904104
163. Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H, et al. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2004) 109(25):3149-53. doi:10.1161/01.CIR.0000134704.84454.D2
164. Wirtz TH, Tillmann S, Strussmann T, Kraemer S, Heemskerk JW, Grottke O, et al. Platelet-derived MIF: a novel platelet chemokine with distinct recruitment properties. Atherosclerosis (2015) 239(1):1-10. doi:10.1016/j.atherosclerosis.2014.12.039
165. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest (1998) 101(2):353-63. doi:10.1172/JCI1195
166. Boisvert WA, Rose DM, Johnson KA, Fuentes ME, Lira SA, Curtiss LK, et al. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol (2006) 168(4):1385-95. doi:10.2353/ajpath.2006.040748
167. Chen Z, Sakuma M, Zago AC, Zhang X, Shi C, Leng L, et al. Evidence for a role of macrophage migration inhibitory factor in vascular disease. Arterioscler Thromb Vasc Biol (2004) 24(4):709-14. doi:10.1161/01.ATV.0000119356.35748.9e
168. Noels H, Bernhagen J, Weber C. Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med (2009) 19(3):76-86. doi:10.1016/j.tcm.2009.05.002
169. White DA, Su Y, Kanellakis P, Kiriazis H, Morand EF, Bucala R, et al. Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction. J Mol Cell Cardiol (2014) 69:32-42. doi:10.1016/j.yjmcc.2014.01.015
170. Liehn EA, Kanzler I, Konschalla S, Kroh A, Simsekyilmaz S, Sönmez TT, et al. Compartmentalized protective and detrimental effects of endogenous macrophage migration-inhibitory factor mediated by CXCR2 in a mouse model of myocardial ischemia/reperfusion. Arterioscler Thromb Vasc Biol (2013) 33(9):2180-6. doi:10.1161/ATVBAHA.113.301633